Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q2 FY25 results · Jul–Sep 2024
Glenmark Pharmaceuticals reported revenue from operations of ₹3,433.80 crore (up 7.1% from Q2 FY24) and net profit of ₹354.49 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,433.80 | 3,207.38 | +7.1% | 3,244.19 | +5.8% |
| Other income | 39.42 | 1.70 | 23x | 31.49 | +25.2% |
| Total income | 3,473.21 | 3,209.07 | +8.2% | 3,275.68 | +6.0% |
| Profit before tax | 472.57 | (124.36) | Turned profit | 462.33 | +2.2% |
| Net profit for the period | 354.49 | (63.55) | Turned profit | 340.24 | +4.2% |
| EPS, basic (₹) | 12.55 | (2.90) | Turned profit | 12.06 | +4.1% |
| Net margin (%) | 10.3 | -2.0 | 10.5 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,636.10 | 2,233.42 | +18.0% | 2,329.54 | +13.2% |
| Other income | 83.08 | 46.22 | +79.8% | 55.65 | +49.3% |
| Total income | 2,719.18 | 2,279.63 | +19.3% | 2,385.18 | +14.0% |
| Profit before tax | 795.06 | 389.37 | +104.2% | 618.31 | +28.6% |
| Net profit for the period | 595.06 | 302.35 | +96.8% | 453.73 | +31.1% |
| EPS, basic (₹) | 21.09 | 10.72 | +96.7% | 16.08 | +31.2% |
| Net margin (%) | 22.6 | 13.5 | 19.5 |
Consolidated
- Filed with BSE
- 15 Nov 2024, 13:36 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 15 Nov 2024, 13:36 IST
- Board meeting
- 14 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE